Published in Law and Health Weekly, September 22nd, 2007
This trend article is an immediate alert from NewsRx to identify the most recent news developments at Takeda Chemical Industries.
Report 1: Takeda Pharmaceutical Company Limited ("Takeda") announced today that its investigational compound TAK-491 has entered into Phase 3 clinical stage in the U.S. and Europe. TAK-491 is an angiotensin receptor blocker (ARB) discovered by Takeda and its mechanism of action is to lower blood pressure by inhibiting action of a vasopressor hormone Angiotensin II.
TAK-491 is expected to show stronger anti-hypertensive...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Law and Health Weekly